Antipsychotic Medication Adherence in Schizophrenia

Psychiatric Clinics of North America

Volumn 30, Issue 3, 2007, Pages 437-452

  Byerly, Matthew J ^a   Nakonezny, Paul A ^a   Lescouflair, Emmeline ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

BEHAVIOR; CLINICAL ASSESSMENT; COMMUNITY; COMMUNITY CARE; CORRELATION FUNCTION; DISEASE SEVERITY; ELECTRONICS; FAMILY; FEASIBILITY STUDY; GROUP THERAPY; HOSPITAL READMISSION; HUMAN; INTERVENTION STUDY; LITERATURE; MONITORING; PATIENT COMPLIANCE; POPULATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RECURRENT DISEASE; RESEARCH; REVIEW; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; SYMPTOM;

ANTIPSYCHOTIC AGENTS; HUMANS; INTERVENTION STUDIES; PATIENT COMPLIANCE; SCHIZOPHRENIA;

EID: 34548018083     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2007.04.002     Document Type: Review

References (53)

1. Velligan D.I., Lam Y.W., Glahn D.C., et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 32 4 (2006) 724-742
2. Diaz E., Levine H.B., Sullivan M.C., et al. Use of the medication event monitoring system to estimate medication compliance in patients with schizophrenia. J Psychiatry Neurosci 26 4 (2001) 325-329
3. Diaz E., Neuse E., Sullivan M.C., et al. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 65 3 (2004) 354-360
4. Byerly M., Fisher R., Whatley K., et al. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res 133 2-3 (2005) 129-133
5. Byerly M.J., Fisher R., Carmody T., et al. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 66 8 (2005) 997-1001
6. Nakonezny P.A., and Byerly M.J. Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics. Schizophr Res 82 1 (2006) 107-114
7. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 5 (2005) 487-497
8. Young J.L., Zonana H.V., and Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 14 2 (1986) 105-122
9. Fenton W.S., Blyler C.R., and Heinssen R.K. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 23 4 (1997) 637-651
10. Lacro J.P., Dunn L.B., Dolder C.R., et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63 10 (2002) 892-909
11. Farmer K.C. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 21 6 (1999) 1074-1090 [discussion: 1073]
12. Wyatt R.J. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17 2 (1991) 325-351
13. Lieberman J.A., Sheitman B., Chakos M., et al. The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. J Clin Psychopharmacol 18 2 Suppl 1 (1998) 20S-24S
14. Olfson M., Mechanic D., Hansell S., et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 51 2 (2000) 216-222
15. Weiden P.J., and Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 21 3 (1995) 419-429
16. Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res Dec 19, 1997;28(2-3):199-206.
17. Weiden P.J., Kozma C., Grogg A., et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 55 8 (2004) 886-891
18. Steadman H.J., Mulvey E.P., Monahan J., et al. Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Arch Gen Psychiatry 55 5 (1998) 393-401
19. Leslie D.L., and Rosenheck R. Shifting to outpatient care? Mental health care use and cost under private insurance. Am J Psychiatry 156 8 (1999) 1250-1257
20. Mauskopf J.A., David K., Grainger D.L., et al. Annual health outcomes and treatment costs for schizophrenia populations. J Clin Psychiatry 60 Suppl 19 (1999) 14-19 [discussion: 20-2]
21. Zygmunt A., Olfson M., Boyer C.A., et al. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 159 10 (2002) 1653-1664
22. Dolder C.R., Lacro J.P., Leckband S., et al. Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol 23 4 (2003) 389-399
23. McDonald H.P., Garg A.X., and Haynes R.B. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288 22 (2002) 2868-2879
24. O'Donnell C., Donohoe G., Sharkey L., et al. Compliance therapy: a randomised controlled trial in schizophrenia. BMJ 327 7419 (2003) 834
25. Gray R., Leese M., Bindman J., et al. Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial. Br J Psychiatry 189 (2006) 508-514
26. Li Z., and Arthur D. Family education for people with schizophrenia in Beijing, China: randomised controlled trial. Br J Psychiatry 187 (2005) 339-345
27. Pitschel-Walz G., Bauml J., Bender W., et al. Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich Psychosis Information Project Study. J Clin Psychiatry 67 3 (2006) 443-452
28. Vreeland B., Minsky S., Yanos P.T., et al. Efficacy of the team solutions program for educating patients about illness management and treatment. Psychiatr Serv 57 6 (2006) 822-828
29. Kemp R., Hayward P., Applewhaite G., et al. Compliance therapy in psychotic patients: randomised controlled trial. BMJ 312 7027 (1996) 345-349
30. Kemp R., Kirov G., Everitt B., et al. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 172 (1998) 413-419
31. Morisky D.E., Green L.W., and Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24 1 (1986) 67-74
32. Dolder C.R., Lacro J.P., Dunn L.B., et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents?. Am J Psychiatry 159 1 (2002) 103-108
33. Rosenheck R., Chang S., Choe Y., et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 61 5 (2000) 382-386
34. Cabeza I.G., Amador M.S., Lopez C.A., et al. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 41 2 (2000) 349-355
35. Grunebaum M.F., Weiden P.J., and Olfson M. Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study. J Clin Psychiatry 62 5 (2001) 394-399 [quiz: 400-1]
36. Gianfrancesco F.D., Rajagopalan K., Sajatovic M., et al. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Res 144 2-3 (2006) 177-189
37. Lehman A.F., Lieberman J.A., Dixon L.B., et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161 2 Suppl (2004) 1-56
38. Miller A.L., Hall C.S., Buchanan R.W., et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 65 4 (2004) 500-508
39. Kane J.M., Leucht S., Carpenter D., et al. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64 Suppl 12 (2003) 5-19
40. Crawford R., and Forrest A. Controlled trial of depot fluphenazine in out-patient schizophrenics. Br J Psychiatry 124 (1974) 385-391
41. del Giudice J., Clark W.G., and Gocka E.F. Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics 16 1 (1975) 32-36
42. Rifkin A., Quitkin F., Rabiner C.J., et al. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. Arch Gen Psychiatry 34 1 (1977) 43-47
43. Falloon I., Watt D.C., and Shepherd M. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med 8 1 (1978) 59-70
44. Hogarty G.E., Schooler N.R., Ulrich R., et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 36 12 (1979) 1283-1294
45. Schooler N.R., Levine J., Severe J.B., et al. Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Arch Gen Psychiatry 37 1 (1980) 16-24
46. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 22 3 (1992) 787-797
47. Nageotte C., Sullivan G., Duan N., et al. Medication compliance among the seriously mentally ill in a public mental health system. Soc Psychiatry Psychiatr Epidemiol 32 2 (1997) 49-56
48. Garavan J., Browne S., Gervin M., et al. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry 39 4 (1998) 215-219
49. Weiden P., Rapkin B., Zygmunt A., et al. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 46 10 (1995) 1049-1054
50. Davis J.M., Matalon L., Watanabe M.D., et al. Depot antipsychotic drugs. Place in therapy. Drugs 47 5 (1994) 741-773
51. Adams C.E., Fenton M.K., Quraishi S., et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179 (2001) 290-299
52. McEvoy J.P. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 67 Suppl 5 (2006) 15-18
53. Heyscue B.E., Levin G.M., and Merrick J.P. Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 49 9 (1998) 1232-1234